B
Bone Biologics Corporation (BBLG)
1.11
0.00 (0.00%)
Get all premium features to the best stock analysis tool
1.11
0.00 (0.00%)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Name | Position |
|---|---|
| Mr. Jeffrey Frelick | CEO & President |
| Ms. Deina H. Walsh CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | 8-K | form8-k.htm |
| 2026-03-02 | 10-K | form10-k.htm |
| 2026-01-08 | 8-K | form8-k.htm |
| 2025-11-14 | 10-Q | form10-q.htm |
| 2025-09-26 | S-8 | forms-8.htm |
| 2025-09-04 | 8-K | form8-k.htm |
| 2025-08-29 | CORRESP | filename1.htm |
| 2025-08-14 | 10-Q | form10-q.htm |
| 2025-06-26 | 8-K | form8-k.htm |
| 2025-06-24 | S-3 | forms-3.htm |